Patents by Inventor Alex J. Harvey

Alex J. Harvey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NPP1 FUSION PROTEINS
    Publication number: 20230129977
    Abstract: The present invention provides a novel fusion polypeptide containing a catalytic domain of NPP1 fused to a targeting moiety, nucleic acids encoding the fusion polypeptide, a vector containing the nucleic acid integrated thereinto, a host cell transformed with the vector and pharmaceutical compositions comprising the fusion polypeptide.
    Type: Application
    Filed: August 11, 2022
    Publication date: April 27, 2023
    Inventors: Anthony Quinn, Alex J. Harvey, Zhinan Xia
  • Lysosomal storage disease enzymes
    Patent number: 11560554
    Abstract: The present invention provides compositions of recombinant human lysosomal acid lipase having particular glycosylation patterns for internalization into target cells, a vector containing the nucleic acid encoding human lysosomal acid lipase, a host cell transformed with the vector, pharmaceutical compositions comprising the recombinant human lysosomal acid lipase and method of treating conditions associated with lysosomal acid lipase deficiency.
    Type: Grant
    Filed: November 9, 2020
    Date of Patent: January 24, 2023
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Anthony Quinn, Alex J. Harvey
  • NPP1 FUSION PROTEINS
    Publication number: 20210301268
    Abstract: The present invention provides a novel fusion polypeptide containing a catalytic domain of NPP1 fused to a targeting moiety, nucleic acids encoding the fusion polypeptide, a vector containing the nucleic acid integrated thereinto, a host cell transformed with the vector and Pharmaceutical compositions comprising the fusion polypeptide.
    Type: Application
    Filed: November 25, 2020
    Publication date: September 30, 2021
    Inventors: Anthony Quinn, Alex J. Harvey, Zhinan Xia
  • LYSOSOMAL STORAGE DISEASE ENZYMES
    Publication number: 20210171922
    Abstract: The present invention provides compositions of recombinant human lysosomal acid lipase having particular glycosylation patterns for internalization into target cells, a vector containing the nucleic acid encoding human lysosomal acid lipase, a host cell transformed with the vector, pharmaceutical compositions comprising the recombinant human lysosomal acid lipase and method of treating conditions associated with lysosomal acid lipase deficiency.
    Type: Application
    Filed: November 9, 2020
    Publication date: June 10, 2021
    Inventors: Anthony QUINN, Alex J. HARVEY
  • Lysosomal storage disease enzymes
    Patent number: 10858638
    Abstract: The present invention provides compositions of recombinant human lysosomal acid lipase having particular glycosylation patterns for internalization into target cells, a vector containing the nucleic acid encoding human lysosomal acid lipase, a host cell transformed with the vector, pharmaceutical compositions comprising the recombinant human lysosomal acid lipase and method of treating conditions associated with lysosomal acid lipase deficiency.
    Type: Grant
    Filed: July 9, 2019
    Date of Patent: December 8, 2020
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Anthony Quinn, Alex J. Harvey
  • LYSOSOMAL STORAGE DISEASE ENZYMES
    Publication number: 20200063113
    Abstract: The present invention provides compositions of recombinant human lysosomal acid lipase having particular glycosylation patterns for internalization into target cells, a vector containing the nucleic acid encoding human lysosomal acid lipase, a host cell transformed with the vector, pharmaceutical compositions comprising the recombinant human lysosomal acid lipase and method of treating conditions associated with lysosomal acid lipase deficiency.
    Type: Application
    Filed: July 9, 2019
    Publication date: February 27, 2020
    Inventors: Anthony Quinn, Alex J. Harvey
  • Lysosomal storage disease enzymes
    Patent number: 10407671
    Abstract: The present invention provides compositions of recombinant human lysosomal acid lipase having particular glycosylation patterns for internalization into target cells, a vector containing the nucleic acid encoding human lysosomal acid lipase, a host cell transformed with the vector, pharmaceutical compositions comprising the recombinant human lysosomal acid lipase and method of treating conditions associated with lysosomal acid lipase deficiency.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: September 10, 2019
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Anthony Quinn, Alex J. Harvey
  • TRANSGENE EXPRESSION IN AVIANS
    Publication number: 20190082665
    Abstract: A transgenic avian containing in its genome an exogenous nucleotide sequence which includes a promoter component and a vector with reduced promoter interference wherein the exogenous nucleotide sequence is integrated into the genome and the avian.
    Type: Application
    Filed: November 29, 2018
    Publication date: March 21, 2019
    Inventors: Alex J. Harvey, Jeffrey C. Rapp
  • Method of using a transgenic chicken to produce exogenous proteins in its eggs
    Patent number: 10182561
    Abstract: A transgenic avian containing in its genome an exogenous nucleotide sequence which includes a promoter component and a vector with reduced promoter interference wherein the exogenous nucleotide sequence is integrated into the genome and the avian.
    Type: Grant
    Filed: June 14, 2016
    Date of Patent: January 22, 2019
    Assignee: ALEXION PHARMACEUTICALS, INC.
    Inventors: Alex J. Harvey, Jeffrey C. Rapp
  • LYSOSOMAL STORAGE DISEASE ENZYMES
    Publication number: 20170314000
    Abstract: The present invention provides compositions of recombinant human lysosomal acid lipase having particular glycosylation patterns for internalization into target cells, a vector containing the nucleic acid encoding human lysosomal acid lipase, a host cell transformed with the vector, pharmaceutical compositions comprising the recombinant human lysosomal acid lipase and method of treating conditions associated with lysosomal acid lipase deficiency.
    Type: Application
    Filed: February 10, 2017
    Publication date: November 2, 2017
    Inventors: ANTHONY QUINN, Alex J. Harvey
  • NPP1 FUSION PROTEINS
    Publication number: 20170145393
    Abstract: The present invention provides a novel fusion polypeptide containing a catalytic domain of NPP1 fused to a targeting moiety, nucleic acids encoding the fusion polypeptide, a vector containing the nucleic acid integrated thereinto, a host cell transformed with the vector and pharmaceutical compositions comprising the fusion polypeptide.
    Type: Application
    Filed: January 27, 2017
    Publication date: May 25, 2017
    Inventors: Anthony QUINN, Alex J. HARVEY, Zhinan XIA
  • NPP1 fusion proteins
    Patent number: 9540621
    Abstract: The present invention provides a novel fusion polypeptide containing a catalytic portion of NPP1 fused to a targeting moiety, nucleic acids encoding the fusion polypeptide, a vector containing the nucleic acid integrated thereinto, a host cell transformed with the vector and pharmaceutical compositions comprising the fusion polypeptide.
    Type: Grant
    Filed: August 1, 2014
    Date of Patent: January 10, 2017
    Assignee: ALEXION PHARMACEUTICALS, INC.
    Inventors: Anthony Quinn, Alex J. Harvey, Zhinan Xia
  • PRODUCTION OF TRANSGENIC AVIANS USING IMPROVED RETROVIRAL VECTORS
    Publication number: 20160353718
    Abstract: A transgenic avian containing in its genome an exogenous nucleotide sequence which includes a promoter component and a vector with reduced promoter interference wherein the exogenous nucleotide sequence is integrated into the genome and the avian.
    Type: Application
    Filed: June 14, 2016
    Publication date: December 8, 2016
    Inventors: Alex J. Harvey, Jeffrey C. Rapp
  • Lysosomal Storage Disease Enzyme
    Publication number: 20150030582
    Abstract: The present invention provides compositions of recombinant human lysosomal acid lipase having particular glycosylation patterns for internalization into target cells, a vector containing the nucleic acid encoding human lysosomal acid lipase, a host cell transformed with the vector, pharmaceutical compositions comprising the recombinant human lysosomal acid lipase and method of treating conditions associated with lysosomal acid lipase deficiency.
    Type: Application
    Filed: September 19, 2014
    Publication date: January 29, 2015
    Applicant: SYNAGEVA BIOPHARMA CORP.
    Inventors: Alex J. Harvey, Anthony Quinn
  • NPP1 FUSION PROTEINS
    Publication number: 20150024460
    Abstract: The present invention provides a novel fusion polypeptide containing a catalytic domain of NPP1 fused to a targeting moiety, nucleic acids encoding the fusion polypeptide, a vector containing the nucleic acid integrated thereinto, a host cell transformed with the vector and pharmaceutical compositions comprising the fusion polypeptide.
    Type: Application
    Filed: October 6, 2014
    Publication date: January 22, 2015
    Inventors: Anthony Quinn, Alex J Harvey, Zhinan Xia
  • NPP1 FUSION PROTEINS
    Publication number: 20140377859
    Abstract: The present invention provides a novel fusion polypeptide containing a catalytic portion of NPP1 fused to a targeting moiety, nucleic acids encoding the fusion polypeptide, a vector containing the nucleic acid integrated thereinto, a host cell transformed with the vector and pharmaceutical compositions comprising the fusion polypeptide.
    Type: Application
    Filed: August 1, 2014
    Publication date: December 25, 2014
    Inventors: Anthony Quinn, Alex J. Harvey, Zhinan Xia
  • Avian Derived Antibodies
    Publication number: 20140336362
    Abstract: The invention is drawn to a composition comprising an isolated mixture of cytotoxic anti-CD20 antibody molecules produces in a transgenic avian. The antibody molecules have a heavy chain and a light chain and exhibit an increased level of antibody-dependent cell-mediated cytotoxicity (ADCC) as compared to that of anti-CD20 antibody molecules produced by CHO cells.
    Type: Application
    Filed: July 17, 2014
    Publication date: November 13, 2014
    Applicant: SYNAGEVA BIOPHARMA CORP.
    Inventor: Alex J. Harvey
  • Glycosylation in Avians
    Publication number: 20140298503
    Abstract: Transgenic avians which produce proteins in their oviduct tissue having modified oligosaccharide structures and methods of making such avians are disclosed herein. The invention also includes the modified proteins produced in the transgenic birds.
    Type: Application
    Filed: April 1, 2013
    Publication date: October 2, 2014
    Applicant: Synageva BioPharma Corp.
    Inventor: Alex J. Harvey
  • NPP1 fusion proteins
    Patent number: 8846603
    Abstract: The present invention provides a novel fusion polypeptide containing a catalytic portion of NPP1 fused to a targeting moiety, nucleic acids encoding the fusion polypeptide, a vector containing the nucleic acid integrated thereinto, a host cell transformed with the vector and pharmaceutical compositions comprising the fusion polypeptide.
    Type: Grant
    Filed: March 11, 2011
    Date of Patent: September 30, 2014
    Assignee: Synageva Biopharma Corp.
    Inventors: Anthony Quinn, Alex J. Harvey, Zhinan Xia
  • Production of Transgenic Avians Using Improved Retroviral Vectors
    Publication number: 20140289879
    Abstract: A transgenic avian containing in its genome an exogenous nucleotide sequence which includes a promoter component and a vector with reduced promoter interference wherein the exogenous nucleotide sequence is integrated into the genome and the avian.
    Type: Application
    Filed: February 28, 2014
    Publication date: September 25, 2014
    Inventors: Alex J. Harvey, Jeffrey C. Rapp